bladder cancer

What anti-PD-L1 immunotherapy approval means for urologyUrologist Peter Black, MD, discusses the recent FDA approval of atezolizumab (TECENTRIQ) for the most common form of bladder cancer as well as a complementary diagnostic test.
Why new bladder cancer drug is novelFDA recently granted accelerated approval for atezolizumab (Tecentriq, Genentech), the first drug for bladder cancer that utilizes the body’s immune system. The drug will be available by early June.
Data on PDE-5’s renoprotective role fail to match early resultsA recent human study sought to replicate previous success seen in animal models of reperfusion injury, reports Urology Times SUO internship program member Katie Murray, DO.
Genetics of two bladder cancer variants analyzedUrology Times SUO internship program member Ryan Hutchinson, MD, reports on a presentation on plasmacytoid urothelial carcinoma and adenocarcinoma.
Uro Pipeline: Trial launched for drugs' use in metastatic, hormone-sensitive PCaA novel oral TRT agent, bladder control system, and localized prostate cancer agent are among other treatments in the pipeline discussed in this round-up.
Uro Pipeline: FDA grants priority review to advanced bladder Ca agentAlso look for coverage of products in the pipeline for bladder pain syndrome/interstitial cystitis, prostate cancer, and male infertility.
Trials explore immune checkpoint blockade in NMIBCPeter C. Black, MD, discusses the current state of immune checkpoint inhibition for bladder cancer in this article from Urology Times SUO internship program member William Parker, MD.
AstraZeneca drug a breakthrough therapy for bladder cancerFDA has granted breakthrough therapy designation for durvalumab (MEDI4736, AstraZeneca) for the treatment of urothelial bladder cancer.
Bladder cancer tests: What factors impact results?Urology Times SUO internship program member Katie Murray, DO, reports on a study evaluating the differences in urine cytology and UroVysion FISH testing results among clinically meaningful patient subgroups.
Study weighs impact of BCG shortage on outcomesUrology Times SUO internship program member William Parker, MD, discusses a retrospective review of more than 100 patients at Columbia University Medical Center in New York.